<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3844">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815031</url>
  </required_header>
  <id_info>
    <org_study_id>C4591006</org_study_id>
    <nct_id>NCT04815031</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation of COMIRNATY Intramuscular Injection</brief_title>
  <official_title>General Investigation Targeting the Vaccines (Health Care Providers [HCPs]) Who Are Vaccinated in Early Post-approval Phase (Follow-up Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-marketing Surveillance, Primary Data Collection chotor study of COMIRNATY vaccenees&#xD;
      followed for 11months. Serious adverse events and COVID-19 observed during the follow-up&#xD;
      period will be collected, and the long-term safety of this product will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The healthcare professionals who are vaccinated with this product early after the marketing&#xD;
      approval of COMIRNATY(participants in the Investigation of Health Status of Recipients&#xD;
      Vaccinated First conducted by the Science Research Group of the Ministry of Health, Labour&#xD;
      and Welfare) will be followed for 11 months from the day following 28 days after the final&#xD;
      vaccination of this product (end date of observation period in Investigation of Health Status&#xD;
      of Recipients Vaccinated First) to 12 months after the final vaccination of this product,&#xD;
      information on serious adverse events and COVID-19 observed during the follow-up period will&#xD;
      be collected, and the long-term safety of this product will be assessed (to be conducted as&#xD;
      11-month follow-up investigation after completion of Investigation of Health Status of&#xD;
      Recipients Vaccinated First).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 7, 2021</start_date>
  <completion_date type="Anticipated">December 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with serious Adverse Events</measure>
    <time_frame>11 months from the day following 28 days after the final vaccination of COMIRNATY</time_frame>
    <description>The long-term safety of this product will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects withe serious Adverse Events</measure>
    <time_frame>11months from the day following 28days after the final vaccination of COMIRNATY</time_frame>
    <description>The long-term safety of this product will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with severe COVID-19</measure>
    <time_frame>11 months from the day following 28 days after the final vaccination of COMIRNATY</time_frame>
    <description>The long-term safety of this procuct will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with severe COVID-19</measure>
    <time_frame>11 months from the day following 28 days after final vaccination of COMIRNATY</time_frame>
    <description>The long-term safety of this produt will be assessed.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>COMIRNATY</arm_group_label>
    <description>COVID-19 mRNA vaccine (nucleoside-modified)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2</intervention_name>
    <description>Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose. Individuals 16 years of age and older.</description>
    <arm_group_label>COMIRNATY</arm_group_label>
    <other_name>COMIRNATY</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who have been vaccinated with this product and have consented to participate&#xD;
        in this study during participation in the Investigation of Health Status of Recipients&#xD;
        Vaccinated First at contract sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have participated in the Investigation of Health Status of Recipients&#xD;
             Vaccinated First and have provided written consent to continue participation in this&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PfizerLocal Country Office</name>
      <address>
        <city>Tokyo</city>
        <zip>1518589</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4591006</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19, Post-Marketing Surveillance,COMIRNATY,Vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

